Clopidogrel and Proton Pump Inhibitors

We have just receive some indication from the manufacturers (Sanofi Aventis + Bristol-Myer Squibb ) that Clopidogrel-containing medicines and proton pump inhibitors (PPIs) ‘should be avoided unless absolutely necessary’. The preliminary studies indicate a cytochrome P450-type interaction. Clopidogrel is a pro-drug which is metabolised in the liver, partially by the cytochrome P450 complex. Hence any […]